BRCA1 and ovarian carcinoma: From 2004, the Department of Genetics of National Institute of Oncology, Budapest, Hungary, has been involved in the BRCA1/2 germline mutation screening of the enrolled high-risk Hungarian breast and ovarian cancer patients.